Amicogen (CEO Park Cheol), a bio-materials, pharmaceuticals, and healthcare specialized company, announced on the 25th that its affiliate, Ropibio, has successfully attracted overseas investment from a European pharmaceutical company.
Due to the current difficulties in the domestic bio investment environment, Ropibio shifted its focus to attracting overseas investment and achieved its first overseas investment of $1 million from European pharmaceutical company A, with plans to pursue additional investments in the future.
Furthermore, starting with this investment, Ropibio plans to maintain a long-term cooperative relationship with pharmaceutical company A. Continuous collaboration is expected not only for the Ailia biosimilar, which has received IND approval for Phase 3 clinical trials in the US, Europe, and Korea, but also for Ropibio’s subsequent pipeline.
The company investing in Ropibio is an excellent pharmaceutical company from the Balkan region of Europe with over 80 years of history and tradition. While many traditional chemical synthesis pharmaceutical companies are focusing on biosimilars as a future growth engine, Ropibio is receiving love calls from multiple pharmaceutical companies.
Ropibio CEO Hong Seung-seo stated, “This overseas investment is seen as a signal for investment and license-out from foreign pharmaceutical companies, and additional results with several overseas pharmaceutical companies will soon emerge.”
Meanwhile, the company stated that despite the challenging business environment, Ropibio is steadily advancing into the global market with the 2024 IND approval for the Ailia biosimilar Phase 3 clinical trial and overseas investment attraction, drawing significant attention. The completion of the Ailia Phase 3 clinical trial is targeted for the end of 2025, with full-scale sales expected to begin in 2027.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
